Novartis AG (NVS) falls 12.7% after Phase III setbacks
Novartis AG (NVS) falls sharply after two late-stage trial failures hit investor confidence. The selloff reflects lost pipeline value, especially for pelacarsen, even as the company’s core business remains profitable and growing.
Novartis AG (NVS) falls 12.7% after back-to-back Phase III setbacks in pelacarsen and del-desiran triggered a sharp repricing of the stock. The decline reflects lost pipeline value and weaker confidence in future growth, even though Novartis still has strong earnings, solid guidance, and a profitable commercial base. For investors, the message is clear: the near-term pressure is clinical and strategic, not an earnings collapse.
Novartis AG (NVS) falls 12.67% after two Phase III setbacks. In extended-hours trading, the ADR printed $139.72 against the prior close of $159.99, while regular-session trading will confirm whether the move holds.
Key Takeaways
NVS fell from $159.99 to $139.72 in after-hours trading, marking a sharp pipeline-driven repricing.
The immediate catalyst was the September 8 failure of the Phase III HARBOR study for del-desiran in DM1.
The larger overhang is pelacarsen’s September 4 failure in the Phase III Lp(a)HORIZON cardiovascular trial.
Novartis entered the selloff with solid operating momentum, including Q2 EPS of $2.41 and strong growth from several key brands.
Investors must separate a damaged pipeline outlook from the company’s still-profitable commercial business.
Why Novartis AG (NVS) Falls After Two Phase III Failures
The clearest catalyst is a rare one-two punch in Novartis’s late-stage drug pipeline. On September 8, Novartis reported that its Phase III HARBOR study failed to show a statistically significant improvement versus placebo on video hand opening time. The trial tested delpacibart etedesiran, also called del-desiran, in patients with myotonic dystrophy type 1. The company’s made the result concrete: the primary endpoint did not succeed.
That announcement arrived only days after pelacarsen failed its own Phase III test. On September 4, Novartis said the Lp(a)HORIZON trial did not reduce major cardiovascular events in high-risk patients with elevated lipoprotein(a). The study enrolled more than 8,300 patients over six years and focused on hard outcomes, including heart attack, stroke, and death.
Pelacarsen carried greater commercial weight. Analyst estimates had placed its potential peak sales between $1.5B and $5.4B. It also targeted lipoprotein(a), a genetically driven cardiovascular risk factor without an approved targeted therapy. Therefore, the failure removed a potential blockbuster and weakened the growth story attached to Novartis’s cardiovascular portfolio.
Reuters described the del-desiran result as the second major trial setback in days and reported pressure on CEO Vas Narasimhan’s acquisition strategy. Novartis acquired Avidity in a deal valued at $12B, making the setback more sensitive than an ordinary research-stage disappointment. The market is now judging both the individual drugs and the capital allocation behind them.
How Novartis Financials and Valuation Frame the NVS Selloff
The selloff is not an earnings collapse. Novartis reported Q2 2026 EPS of $2.41, above the $2.20 estimate, for a 9.5% surprise. Its recent earnings history shows five beats in seven quarters. Management also reaffirmed full-year guidance after the second quarter.
The company’s current financial profile remains substantial. Novartis has a $304.10B market capitalization, EPS of $6.62, a P/E ratio of 24.17, and a 2.96% dividend yield. Those figures show a profitable global drugmaker, not a distressed biotechnology company. However, a 24.17 P/E places a high value on earnings durability and future product launches.
That distinction matters. A clinical failure can reduce the value of future revenue before it affects reported EPS. The market therefore reprices the pipeline first, even when current sales and earnings remain healthy. In this case, the after-hours decline reflects lost growth optionality and lower confidence in research execution.
The price action also overwhelms NVS’s normally defensive profile. Its beta is 0.49, which points to lower historical sensitivity to broad market swings. Yet company-specific clinical news can overpower that stability. The move from $159.99 to $139.72 shows how quickly drug development risk can dominate a large-cap pharmaceutical stock.
Novartis Growth Brands Provide a Commercial Cushion
Novartis still has a broad commercial base. The company says its medicines reach 296 million people worldwide. Its priority brands also delivered strong Q2 2026 growth, according to the company’s earnings update.
Kisqali sales grew 43% at constant currency. Kesimpta increased 32%, while Scemblix rose 89%. Pluvicto gained 43%, and Leqvio advanced 59%. These results show that Novartis is not dependent on one product or one therapeutic area. The company competes across oncology, immunology, cardiovascular medicine, neuroscience, and rare disease.
The competitive backdrop remains demanding. Novartis operates alongside AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda. These companies compete for clinical talent, launch opportunities, acquisitions, and investor capital.
That peer group explains why the pipeline matters so much. Strong current brands can support revenue today, but future medicines sustain growth after patents mature and competition increases. Two late-stage failures in four days therefore create a strategic problem even when the commercial portfolio continues to perform.
The practical framework starts with separating three risks. First, pelacarsen represents a lost growth asset and a lost opportunity in cardiovascular medicine. Its failed outcomes trial removes the commercial potential implied by the $1.5B to $5.4B peak-sales estimates.
Second, del-desiran raises questions about pipeline execution and acquisition discipline. The drug came through the $12B Avidity transaction, so the HARBOR failure adds strategic weight to the clinical result. Back-to-back misses create a stronger challenge to confidence than either event would create alone.
Third, investors can measure the damage against Novartis’s operating foundation. Q2 EPS beat estimates by 9.5%, management reaffirmed full-year guidance, and five major growth brands posted double-digit gains. Those facts support the view that the immediate problem centers on future pipeline value, not a breakdown in current demand.
Valuation still requires discipline. A 24.17 P/E and a 2.96% dividend yield can appeal to long-term holders, but neither figure cancels clinical risk. At $139.72, the after-hours price remains above the 52-week low of $117.9791 and below the 52-week high of $165.425. That range offers context, not a verdict.
For investors assessing the decline, the strongest signal is the contrast between current execution and future optionality. The earnings base remains supported by Kisqali, Kesimpta, Scemblix, Pluvicto, and Leqvio. Meanwhile, the failed pelacarsen and del-desiran programs demand a lower level of confidence in pipeline-led growth.
Novartis AG (NVS) falls because two late-stage clinical failures struck within days, with del-desiran adding a fresh shock to the larger pelacarsen overhang. The company still has strong brands, profitable operations, and reaffirmed full-year guidance, but the market has clearly marked down its pipeline credibility. Regular-session trading will show whether investors treat the after-hours move as a lasting reset or an initial overreaction.
NVS is down because Novartis reported two major Phase III trial failures in quick succession, including pelacarsen and del-desiran. Those setbacks reduced confidence in the company’s future pipeline and growth prospects.
+Should I buy NVS stock now?
The article suggests caution rather than urgency. Novartis still has strong earnings and a healthy commercial business, but the pipeline damage means investors should wait for more clarity on valuation and sentiment.
+Did Novartis miss earnings?
No. Novartis recently beat Q2 EPS estimates and reaffirmed full-year guidance. The stock is falling because of clinical trial failures, not because of an earnings miss.
+What does the Phase III failure mean for Novartis investors?
It means the company may have lost a meaningful future revenue driver, especially with pelacarsen. Investors should expect pressure on sentiment until the pipeline story stabilizes.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on NVS?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
